Atjaunināt sīkdatņu piekrišanu

E-grāmata: The Coronavirus Pandemic and the Future: Virology, Epidemiology, Translational Toxicology and Therapeutics, Volume 2

Edited by (Integrated Laboratory Systems (ILS) Inc., USA), Edited by (Chesapeake Cardiac Care, USA), Edited by (IQVIA, USA), Edited by (University of Bradford, UK), Edited by (Centre of BioMedical Research, SGPGIMS Campus, India), Edited by (Edentox Associates, UK)
  • Formāts: 650 pages
  • Izdošanas datums: 27-Apr-2022
  • Izdevniecība: Royal Society of Chemistry
  • ISBN-13: 9781839166839
  • Formāts - PDF+DRM
  • Cena: 118,96 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 650 pages
  • Izdošanas datums: 27-Apr-2022
  • Izdevniecība: Royal Society of Chemistry
  • ISBN-13: 9781839166839

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

By addressing considerations of efficacy and safety of drugs and chemicals used to combat COVID-19, virtually in real-time, this book documents and highlights the advances in science and place the toxicology, pharmaceutical science, public health and medical community in a better position to advise in future epidemics.

This second volume chronicles the later stages of the outbreak of SARS-Cov-2 (COVID-19) and delineates the role of several disciplines in therapeutic and control measures highliting the response from specific coutries of note and efforts to repurpose and produce new therapeutics and vaccines. By addressing considerations of efficacy and safety of drugs and chemicals used to combat COVID-19, virtually in real-time, this book documents and highlights the advances in science and place the toxicology, pharmaceutical science, public health and medical community in a better position to advise in future epidemics.
In Silico Approaches for Drug Repurposing for SARS-CoV-2 Infection;

Vaccination and Vaccines for COVID-19;

Understanding Emergence of SARS-CoV-2 Viral Variants from a Genomic
Perspective;

Susceptibility and Spread of SARS-Cov-2 in Animals;

Profiling Some Plant-based Immunomodulatory Bioactive Compounds for COVID-19
Prophylaxis and Treatment Based on Indian Traditional Medicine;

The Potential Therapeutic effects of Natural Products, Herbs, Mushrooms
Against COVID-19;

Application of Chinese Herbal Medicine in COVID-19;

COVID-19 Interventional and Therapeutic Clinical Trials: Small Molecules,
Interactions, Outcomes and Opportunities;

A Trend Analysis of COVID-19 Pandemic in Turkey;

The Swedish Approach to COVID-19;

New Zealands Response to the First Wave of COVID-19;

Significant SARS-CoV-2 Variants Circulating Around the World: Origin, Spread
and Phylodynamics;

Survival of SARS-CoV-2 Outside the Body and Methods of Disinfection;

U.S. Regulatory Approaches to Disinfectants for Coronavirus;

Diagnostic Strategies for Early and Point-of-care Detection of COVID-19 in
Clinical and Personalized Settings;

Human Resource Management, Preparedness and Outcomes;

Role of Telehealth during the COVID-19 Pandemic;

Medical Education During the Covid Pandemic: Challenges and Solutions;

Containment Strategies to Prevent Spread in Different Societies and
Cultures;

Effective Health Education, Patient Education, Health Behaviour Change;

Strengthening the Biological and Toxin Weapons Convention after COVID-19:
Reaching Agreement on a Code of Conduct and Biological Security Education at
the 2021 9th Review Conference;

COVID-19 Prevention;

Human Response to Pandemics in History and Medico-anthropological
Correlates;

The COVID-19 Pandemic - Global Lessons for the Future
Michael D. Waters, holds a Ph.D. in Biochemistry from the University of North Carolina School of Medicine at Chapel Hill and a B.S. in Pre-medicine (Chemistry and Biology) from Davidson College. He is a former government scientist with more than 35 years of experience in research and research management positions at EPA and NIH/NIEHS and six years of private sector experience as Chief Scientific Officer at Integrated Laboratory Systems, Inc. His research interests have centered on the evaluation of chemically-induced mutations and altered molecular expression in the etiology of genetic disease. He is a widely-published scientist having published well over 100 peer-reviewed in authoritative international scientific journals. He has edited Mutation Research-Reviews for nearly 20 years and has held adjunct professorships at both the University of North Carolina and at Duke University for many years. He served as President of both the Environmental Mutagen Society and the International Association of Environmental Mutagen Societies (now the Environmental Mutagenesis and Genomics Society and the International Association of Environmental Mutagenesis and Genomics Societies, with more than seven thousand members worldwide). The databases he has developed and a number of his publications are recognized as important advances that have significantly impacted the fields of genetic toxicology, carcinogenesis, toxicogenomics, and risk assessment.